Liu W, Hu H, Li C, Shi Q, Liu C, Liu A
J Headache Pain. 2024; 25(1):206.
PMID: 39587512
PMC: 11587596.
DOI: 10.1186/s10194-024-01913-0.
Gawde P, Shah H, Patel H, Bharathi K, Patel N, Sethi Y
Cureus. 2023; 15(2):e34553.
PMID: 36879707
PMC: 9985459.
DOI: 10.7759/cureus.34553.
Kim Y, Granstein R
Brain Behav Immun Health. 2021; 18:100361.
PMID: 34746878
PMC: 8551410.
DOI: 10.1016/j.bbih.2021.100361.
Chaliha D, Vaccarezza M, Takechi R, Lam V, Visser E, Drummond P
Nutrients. 2020; 12(8).
PMID: 32824835
PMC: 7468811.
DOI: 10.3390/nu12082487.
Negro A, Koverech A, Martelletti P
J Pain Res. 2018; 11:515-526.
PMID: 29563831
PMC: 5848843.
DOI: 10.2147/JPR.S132833.
PACAP38 in human models of primary headaches.
Ashina H, Guo S, Vollesen A, Ashina M
J Headache Pain. 2018; 18(1):110.
PMID: 29453754
PMC: 5815979.
DOI: 10.1186/s10194-017-0821-3.
Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.
Ong J, De Felice M
Neurotherapeutics. 2017; 15(2):274-290.
PMID: 29235068
PMC: 5935632.
DOI: 10.1007/s13311-017-0592-1.
Effects of Voluntary Locomotion and Calcitonin Gene-Related Peptide on the Dynamics of Single Dural Vessels in Awake Mice.
Gao Y, Drew P
J Neurosci. 2016; 36(8):2503-16.
PMID: 26911696
PMC: 4764666.
DOI: 10.1523/JNEUROSCI.3665-15.2016.
Primary Headache Disorders: Focus on Migraine.
Bahra A
Rev Pain. 2015; 5(4):2-11.
PMID: 26525886
PMC: 4590049.
DOI: 10.1177/204946371100500402.
Orofacial pain management: current perspectives.
Romero-Reyes M, Uyanik J
J Pain Res. 2014; 7:99-115.
PMID: 24591846
PMC: 3937250.
DOI: 10.2147/JPR.S37593.
Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres.
Baillie L, Ahn A, Mulligan S
Neuropharmacology. 2012; 63(3):362-7.
PMID: 22691374
PMC: 3399992.
DOI: 10.1016/j.neuropharm.2012.04.016.
5-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons.
Choi I, Cho J, An C, Jung J, Hur Y, Choi J
Br J Pharmacol. 2012; 167(2):356-67.
PMID: 22462474
PMC: 3481043.
DOI: 10.1111/j.1476-5381.2012.01964.x.
Diencephalic and brainstem mechanisms in migraine.
Akerman S, Holland P, Goadsby P
Nat Rev Neurosci. 2011; 12(10):570-84.
PMID: 21931334
DOI: 10.1038/nrn3057.
Chemical mediators of migraine: preclinical and clinical observations.
Gupta S, Nahas S, Peterlin B
Headache. 2011; 51(6):1029-45.
PMID: 21631491
PMC: 3986727.
DOI: 10.1111/j.1526-4610.2011.01929.x.
The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.
Van Der Schueren B, Blanchard R, Murphy M, Palcza J, De Lepeleire I, Van Hecken A
Br J Clin Pharmacol. 2011; 71(5):708-17.
PMID: 21480950
PMC: 3093076.
DOI: 10.1111/j.1365-2125.2010.03869.x.
Pharmacology.
Bolay H, Durham P
Handb Clin Neurol. 2010; 97:47-71.
PMID: 20816410
PMC: 5993437.
DOI: 10.1016/S0072-9752(10)97004-8.
Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.
Durham P, Vause C
CNS Drugs. 2010; 24(7):539-48.
PMID: 20433208
PMC: 3138175.
DOI: 10.2165/11534920-000000000-00000.
Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers.
Hansen J, Petersen J, Wienecke T, Olsen K, Jensen L, Ashina M
J Headache Pain. 2009; 10(2):85-91.
PMID: 19266171
PMC: 3451653.
DOI: 10.1007/s10194-009-0102-x.
Triptans in pregnancy.
Soldin O, Dahlin J, OMara D
Ther Drug Monit. 2008; 30(1):5-9.
PMID: 18223456
PMC: 3644550.
DOI: 10.1097/FTD.0b013e318162c89b.
Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.
Villalon C, Centurion D
Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63.
PMID: 17703282
DOI: 10.1007/s00210-007-0179-1.
